| |
|
 |
|
MODERN RHEUMATOLOGY Vol.12 No.3
>MR12-3
|
| Activated peripheral blood mononuclear cells detected in lupus patients using cDNA coding for proliferating cell nuclear antigen |
|
| Y. Takasaki A1, S. Ando A1, K. Matsumoto A1, H. Yamada A1, K. Ikeda A1, M. Nawata A1, M. Matsushita A1, R. Matsudaira A1, K. Kaneda A1, K. Takeuchi A1, Y. Tokano A1, H. Hashimoto A1 |
| A1 Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan Tel. +81-3-3813-3111 (ext. 3314); Fax +81-3-5800-4893 e-mail: tyoshi@med.juntendo.ac.jp |
| |
Full Text
> Click Here （member's only） |
| |
| Abstract |
| Abstract The expression of proliferating cell nuclear antigen (PCNA) mRNA in peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) was measured by dot blot hybridization using a PCNA cDNA, and correlated with the percentage of PCNA-positive cells detected immunohistochemically using a monoclonal anti-PCNA antibody. PCNA-positive PBMCs were detected in 72.2% of SLE patients (n = 36), which is significantly more than among healthy controls. In addition, among those in whom PCNA expression was detected, the percentage of PBMCs expressing PCNA was significantly higher in SLE patients (mean 2.5% vs. 0.15%). The level of PCNA mRNA was increased in PBMCs from 83.3% of SLE patients, and was significantly correlated with the percentage of PCNA-positive cells (r = 0.54, P < 0.01) and with the disease activity score (r = 0.56, P < 0.01). A longitudinal study of two SLE patients confirmed that PCNA mRNA expression and the percentages of PCNA-positive cells varied in parallel with disease activity. Thus, an analysis of activated PBMCs from SLE patients using PCNA cDNA may be a useful method by which to estimate SLE disease activity. |
| |
| Key words |
| Key words Anti-PCNA monoclonal antibodies ・ Disease activity ・ PCNA cDNA・ Proliferating cell nuclear antigen (PCNA) ・ Systemic lupus erythematosus (SLE) |
|
| |
| 一覧に戻る |
|
|
